Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of Xolair (omalizumab) on airway hyperresponsiveness.

Trial Profile

The effects of Xolair (omalizumab) on airway hyperresponsiveness.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Oct 2015

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2011 Planned end date changed from 1 Sep 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 28 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Planned end date changed from 1 Aug 2008 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top